Vincent Ribrag

Vincent Ribrag

Auto-generated profile, based on publicly available information

Vincent Ribrag

Institut de Cancérologie Gustave Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2001 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FSFlorence Suzan
Florence Suzan
MAMounia Ammor
Mounia Ammor
VRVincent Ribrag
Vincent Ribrag
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen expressed on most B cells and is used to treat B-cell non-Hodgkin's lymphoma.1 Recently, rituximab has been used to treat post-transplantation lymphoproliferative disorders, which may occur after solid-organ and bone marrow transplantation; the prognosis associated with these disorders is usually poor, even if the doses of immunosuppressive drugs are reduced. Rituximab induces profound and durable B-cell depletion without a substantial decrease in serum immunoglobulin levels. Viral infection has rarely been reported after the use of this agent. Hepatitis B reactivation,1,2 visceral varicella–zoster infection,3 and pure red-cell aplasia due to chronic parvovirus B19 infection4 have occurred in patients treated with rituximab, but in all these cases, rituximab was combined with chemotherapy. We describe a fatal reactivation of cytomegalovirus infection after rituximab therapy in a patient with a post-transplantation lymphoproliferative disorder.

1 January 2003 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DGD. Gholam
D. Gholam
FBF. Bibeau
F. Bibeau
AWA. El Weshi
A. El Weshi
JBJ. Bosq
J. Bosq
VRV. Ribrag
V. Ribrag
Primary breast lymphoma (PBL) is a rare form of localized extranodal lymphoma. Few reports are available in the literature concerning its treatment and outcome. Of the 34 cases of PBL seen at our institution over a 25-year period, 20 consecutive cases were treated with CHOP or CHOP-like chemotherapy regimen and had adequate biopsy specimens for histological review. All these 20 PBL were of B-cell origin including one case of Burkitt lymphoma, and 2 cases of low-grade histologic type. Sixteen of the 20 patients achieved a complete remission (CR) and 2 achieved a partial remission (PR) (>75% tumor regression). Two patients had progressive disease while on therapy. With a median follow-up period of 80 months, 6 patients relapsed. Median time to relapse from diagnosis was 23 months (range, 3–41 months). Two of the relapses involved the central nervous system (CNS): isolated CNS relapse in one case and associated with other relapse sites in 1 case. The two patients who achieved a PR after chemotherapy also had disease progression to the CNS, 4 and 8 months after the end of CHOP chemotherapy. All 4 patients died of their disease 3, 6, 10 and 13 months after CNS involvement. Of the 16 centroblastic diffuse large B-cell lymphoma (DLCL), 3 had CNS disease at relapse. Three (15%) of our study patients developed a controlateral breast relapse. Twelve of the initial 20 patients were alive, including 11 with a persistent CR, 6 patients died of their lymphoma and 2 of unrelated diseases. In conclusion, we observed a high incidence of CNS relapse in this group of localized extranodal lymphoma, strongly suggesting that CNS prophylaxis should be associated with systemic chemotherapy in localized PLB.

1 November 2001 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
VRV. Ribrag
V. Ribrag
FBF. Bibeau
F. Bibeau
AWA. El Weshi
A. El Weshi
JFJ. Frayfer
J. Frayfer
CFC. Fadel
C. Fadel
PFP. Fenaux
P. Fenaux
Limited data are available concerning treatment and outcome of primary lymphoma of the breast (PLB), especially after CHOP (cyclophosphamide, hydroxydoxorubicin, vincristine, prednisone) chemotherapy. We retrospectively reviewed 20 consecutive cases of localized PLB seen at our institution over a 20 year period. All PLB were of B‐cell origin: treatment was CHOP or a CHOP‐like regimen in all patients. Sixteen of the 20 patients achieved complete remission (CR) and two achieved partial remission (> 75% tumour regression). Two patients had progressive disease on therapy. With a median follow‐up of 54 months, six patients relapsed after 8–66 months. Two of the relapses involved the central nervous system (CNS) (isolated in one case, associated with other sites of relapse in the other). The two patients who achieved partial remission also had progression in the CNS, 4 and 8 months after the end of CHOP chemotherapy. All four patients have died as a result of their disease 3, 6, 10 and 13 months after CNS relapse. Of the 16 centroblastic diffuse large B‐cell lymphoma (DLCL), three had CNS disease at relapse. We also observed three (15%) controlateral breast relapses. Thirteen of the initial 20 patients are alive in CR, six patients have died as a result of their lymphoma and one of unrelated disease. In conclusion, we observed a high incidence of CNS relapse in this group of localized extranodal lymphoma, strongly suggesting that CNS prophylaxis should be associated with systemic chemotherapy in localized PLB.

31 May 2008 in European Journal of Radiology
Verified
Journal Article
Closed access
PDF file
VRVincent Ribrag
Vincent Ribrag
DVDaniel Vanel
Daniel Vanel
SLSophie Leboulleux
Sophie Leboulleux
JLJean Lumbroso
Jean Lumbroso
DCDominique Couanet
Dominique Couanet
MSMartin Schlumberger
Martin Schlumberger

12 October 2012 in Haematologica
Verified
Journal Article
Open access
PDF file
VRV. Ribrag
V. Ribrag
DCD. Caballero
D. Caballero
CFC. Ferme
C. Ferme
Emanuele ZuccaEmanuele Zucca
Emanuele Zucca
RAR. Arranz
R. Arranz
FCF. Cavalli
F. Cavalli
This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m2 administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressive non-Hodgkin’s lymphoma. Patients were divided into two cohorts: those with non-cutaneous peripheral T-cell lymphoma (n=34) and those with other lymphomas (n=33). Efficacy was evaluated using the International Working Group criteria (1999). Of the 29 evaluable patients with non-cutaneous peripheral T-cell lymphoma, six had a response (overall response rate 20.7%; 95% confidence interval, 8.0%–39.7%), including two complete responses and four partial responses. No responses occurred in the 30 evaluable patients with other lymphomas (including 27 B-cell lymphomas). The most common plitidepsin-related adverse events were nausea, fatigue and myalgia (grade 3 in <10% of cases). Severe laboratory abnormalities (lymphopenia, anemia, thrombocytopenia, and increased levels of transaminase and creatine phosphokinase) were transient and easily managed by plitidepsin dose adjustments. The pharmacokinetic profile did not differ from that previously reported in patients with solid tumors. In conclusion, plitidepsin monotherapy has clinical activity in relapsed/refractory T-cell lymphomas. Combinations of plitidepsin with other chemotherapeutic drugs deserve further evaluation in patients with non-cutaneous peripheral T-cell lymphoma. (clinicaltrials.gov identifier: NCT00884286)

2 April 2009 in Blood
Verified
Journal Article
Closed access
VRVincent Ribrag
Vincent Ribrag
SKSerge Koscielny
Serge Koscielny
RCRene Olivier Casasnovas
Rene Olivier Casasnovas
CCCecile Cazeneuve
Cecile Cazeneuve
PBPauline Brice
Pauline Brice
GSGilles Salles
Gilles Salles
Hodgkin lymphoma is a highly curable malignancy, but treatment outcome might be influenced by inherited gene polymorphisms determining anticancer agent metabolism. We prospectively collected peripheral blood lymphocytes from 313 patients with Hodgkin lymphomas to analyze GSTP1, GSTM1, GSTT1, UGT1A1, and CYP3A4 enzyme gene polymorphisms. All patients were treated with chemotherapy, associated with radiotherapy when they had localized disease. There was no difference for GSTP1, GSTM1, and GSTT1 as well as for UGT1A1 and CYP3A4 polymorphism distributions between Hodgkin lymphoma patients and healthy controls. Patients carrying 1 or 2 UGT1A1*28 allele had a significantly (P < .05) better freedom from progression and time to treatment failure than those homozygous for the UGT1A1 TA6/TA6 allele. Multivariate prognostic analyses showed that the UGT1A1 polymorphism was as an independent prognostic parameter for all the studied endpoints, the wild-type homozygous UGT1A1 TA6/TA6 genotype being associated with a significantly worse prognosis than genotypes with at least one UGT1A1*28 allele (overall survival; relative risk [RR] = 2.54, 95% confidence interval [CI], 1.05-6.14; P = .04; freedom from progression, RR = 2.70, 95% CI, 1.37-5.31; P = .004; time to treatment failure, RR = 2.37, 95% CI, 1.28-4.40, P = .006). UGT1A1 polymorphism on TA repeats, which are thought to determine several anticancer drugs metabolism, influence Hodgkin lymphoma patient outcome.